Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies

European Journal of Nuclear Medicine

Volumn 27, Issue 7, 2000, Pages 753-765

  Behr, Thomas M ^b   Béhé, Martin ^c   Löhr, Martin ^c   Sgouros, George ^a   Angerstein, Christa ^c   Wehrmann, Eike ^c   Nebendahl, Klaus ^c   Becker, Wolfgang ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c NONE

Author keywords

Auger conversion electron emitter; Indium 111; Internalizing monoclonal antibody; Radioimmunotherapy; Radiometal; Yttrium 90

Indexed keywords

EDRECOLOMAB; INDIUM 111; IODINE 125; IODINE 131; RADIOACTIVE IODINE; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTERNALIZATION; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NONHUMAN; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR GROWTH;

EID: 0008772186     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590000272     Document Type: Article

References (51)

1. 1. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review "Of Mice and Men". Hybridoma 1997; 16: 101-107.
2. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995; 346: 336-340.
3. 3. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997; 38: 409-418.
4. 4. Blumenthal RD, Sharkey RM, Goldenberg DM. Overcoming dose-limiting, radioantibody-induced myelotoxicity. In: Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press; 1995: 295-314.
5. 5. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Siegel JA, Goldenberg DM. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997; 38: 858-870.
6. 6. Meredith RF, Khazaeli MB, Plott WE, Spencer SA, Wheeler RH, Brady LW, Woo DV, LoBuglio AF. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995; 36: 2229-2233.
7. 7. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, St. Germain J, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14: 1787-1797.
8. 125I in mammalian cells. Radiat Res 1987; 111: 305-318.
9. 9. Martin RF, Haseltine WA. Range of radiochemical damage to DNA with decay of iodine-125. Science 1981; 213: 896-898.
10. 10. Weber DA, Eckerman KF, Dillman LT, Ryman JC, eds. MIRD: radionuclide data and decay schemes. New York: MIRD Committee of the Society of Nuclear Medicine, 1989.
11. 11. Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Old LJ, Larson SM. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled monoclonal antibody. J Nucl Med 1996; 37: 1052-1057.
12. 125I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res 1989; 49: 2952-2958.
13. 13. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci 1979; 76: 1438-1442.
14. 14. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer JP. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957-972.
15. 15. Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G. The epithelial surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.
16. 16. Kassis A, Adelstein SJ, eds. Radiolabeled IUdr. J Nucl Med 1996; 37 Suppl: 1S-32S.
17. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992; 52: 121-126.
18. 125I-labeled monoclonal antibody 17-1A against human colon carcinoma [abstract]. Proc Am Assoc Cancer Res 1994; 35: 648.
19. 131I-monoclonal antibody A33 [abstract]. Proc Am Assoc Cancer Res 1993; 34: 477.
20. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998; 76: 738-748.
21. 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 1992; 52: 4728-4734.
22. 22. Velders MP, van Rhijn CM, Briaire IH, Jan Fleuren GJ, Warnaar SO, Litvinov SV. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995; 55: 4398-4403.
23. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36: 430-441.
24. 24. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Frank M, Schmidberger H, Raue F, Becker W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmuno-chemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 1997; 57: 5309-5319.
25. 25. Brechbiel MW, Gansow OA, Achter RW, Schlom J, Esteban JM, Simpson DE, Colcher D. Synthesis of 1-(p-isothio-cyanobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg Chem 1986; 25: 2772-2781.
26. 26. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM. Overcoming nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy in a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80: 2591-2610.
27. 27. Goldenberg DM, Witte S, Elster K. A new human tumor serially transplantable in the golden hamster. Transplantation 1966; 4: 760-764.
28. 28. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-694.
29. 90Y dosimetry in the nude mouse: evaluation of three dosimetry models in relation to observed biological effects in radioimmunotherapy of human colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg (TN) 1996. 1999, vol 1: 257-271.
30. 30. Furhang EE, Sgouros G, Chui CS. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys 1996; 23: 759-764.
31. 31. Goddu SM, Howell RW, Rao DV. Generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J Nucl Med 1995; 36: 1923-1927.
32. 32. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35: 303-316.
33. 33. Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert K, Siegel JA, Goldenberg DM. Y-90-dosimetry in nude mice requires accounting for cross-organ radiation: evaluation of three dosimetry models in relation to observed biological effects. J Nucl Med 1996; 37: 102P.
34. 34. Yoriyaz H, Stabin M. Electron and photon transport in a model of a 30 g mouse. J Nucl Med 1997; 38: 228P.
35. 35. Blumenthal RD, Sharkey RM, Forman D, Wong G, Hess J, Goldenberg DM. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp Hematol 1995; 23: 1088-1097.
36. 36. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 1997; 29: 477-485.
37. 125I treatment of thyrotoxicosis. Clin Endocrinol 1976; 5: 225-234.
38. 125I on mouse and rat thyroid. Int J Radiat Biol 1972; 22: 489-499.
39. 125I and x irradiations. Br J Radiol 1970; 43: 542-548.
40. 40. McKillop JH, Doig JA, Kennedy JS, Thomson JA, Greig WR. Laryngeal malignancy following iodine-125 therapy for thyrotoxicosis. Lancet 1978; 2: 1177-1179.
41. 125I] iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res 1988; 48: 2993-2997.
42. 125I]-labelled metaiodobenzylguanidine. Int J Cancer 1990; 45: 1164-1168.
43. 125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res 1996; 56: 5428-5434.
44. 44. Hoefnagel CA, Smets L, Voute PA, de Kraku J. Iodine-125-MIBG therapy for neuroblastoma. J Nucl Med 1991; 32: 361-362.
45. 45. DeSombre ER, Shafii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptor-directed radiotoxicity with Auger-electrons: specificity and mean lethal dose. Cancer Res 1992; 52: 5752-5758.
46. 46. Sastry KSR, Rao DV. Dosimetry of low energy electrons. In: Rao DV, Chandra R, Graham MC, eds. Physics of nuclear medicine: recent advances. Medical Physics Monograph No. 10. Woodbury, NY: American Institute of Physics, American Association of Physicists in Medicine; 1984: 169-208.
47. 47. Feinendegen LE. Biological damage from Auger effect, possible benefits. Radiat Environ Biophys 1975; 12: 85-99.
48. 3HTdR. Radiat Res 1976; 67: 332-343.
49. 125I-bovine serum albumin. Radiat Res 1993; 133: 182-186.
50. 50. Duncan JR, Behr TM, DeNardo S. Intracellular fate of radiometals. J Nucl Med 1997; 38: 829.
51. 51. Sastry KSR. Biological effects of the Auger emitter iodine-125: a review. Report No. 1 APM Nuclear Medicine Task Group No. 6. Med Phys 1992; 19: 1361-1370.